Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMU-366
- Development stage
- Preclinical
- Lead developer
- Immunic
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**IMU-366** is an orally available small molecule inverse agonist of RORγt (RORgT), a nuclear receptor that regulates the differentiation of Th17 T cells and the production of pro-inflammatory cytokines involved in autoimmune diseases. Developed by Immunic Therapeutics following acquisition from 4SC, it demonstrated efficacy in preclinical models of immune and autoimmune conditions. Primarily targeted for autoimmune diseases such as psoriasis, it offers potential for broader applications in Th17-mediated disorders due to its selective modulation of cytokine expression without broad immunosuppression.[1][2][5][8]
02
Targets
RORγt
Beyond the preview
Go deeper on IMU-366.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMU-366.